pharmaphorum
MARCH 2, 2022
Amazon’s encroachment into healthcare advanced a little further this week when the online giant launched a doctor consultation service delivered via its Alexa voice assistant, with the help of telehealth player Teladoc. Users of the service will be able to request non-urgent medical care around the clock, simply by telling Alexa via their Amazon Echo device that they want to speak to a doctor.
Outsourcing Pharma
FEBRUARY 28, 2022
The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
FEBRUARY 28, 2022
Unmet need among over 7000 rare diseases is being addressed in a comprehensive action plan
Roots Analysis
MARCH 3, 2022
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
MARCH 4, 2022
With prospects of an early, accelerated approval for Roche’s Alzheimer’s disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the hope of building its case for the drug. The new placebo-controlled SKYLINE study will enrol 1,250 people aged 60 to 80 with the earliest biological signs of Alzheimer’s – in other words signs of amyloid accumulation in the central nervous system – but no cognitive impairment.
Outsourcing Pharma
MARCH 1, 2022
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Impact Pharmaceutical Services
MARCH 2, 2022
RESEARCH TRIANGLE PARK, NC: 01 March 2022 – In the second half of 2021, IMPACT’s employees continued their generous efforts via the Making an IMPACT (MAI) community service initiative. We continued our charitable and community outreach efforts by taking hybrid approaches to in-person and virtual service activities and celebrated our 6th annual Season of Giving […].
pharmaphorum
FEBRUARY 28, 2022
UK Health Secretary Sajid Javid has said he wants to accelerate the rollout of electronic patient records (EPR) in the NHS, with 90% of NHS trusts using them by the end of 2023. Javid laid out the new target in a speech to the HSJ Digital Transformation Summit, in which he said that current estimates are that one in five NHS trusts still do not have EPR, and so are missing out on a key technology to deliver better, safer care for patients.
Outsourcing Pharma
FEBRUARY 28, 2022
With a specific focus on clinical trials involving treatments for rare diseases, Orphan Reach seeks to build upon the services that conventional CROs offer.
Pharma Times
MARCH 3, 2022
The phase 3 MELODY study reveals that nirsevimab vaccine reduces lower respiratory tract infections
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Marketing Network
MARCH 2, 2022
New findings from an IQVIA report show the biopharmaceutical industry is sparking with activity with an astounding 6,000 products in development and new geographical locations seeing the boom. While it was a concern that COVID-19 would slow down new ventures in the biopharmaceutical sector, the reality has been just the opposite. According to Murray Aitken, IQVIA’s Senior VP and Executive Director of the IQVIA Institute for Human Data Science, “the pandemic has accelerated biopharmac
pharmaphorum
MARCH 2, 2022
There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments. Ben Hargreaves discovers why medical research in the area has shifted from being highly controversial to being backed by major pharma companies and venture capital. The image of psychedelic drugs within medical research is changing.
Outsourcing Pharma
MARCH 3, 2022
The drug discovery firm will work with the Dean Felsher Laboratory, using the companyâs transomics platform to discover therapies for untreatable cancers.
Pharma Times
MARCH 3, 2022
NICE document recommends Amgen’s Lumykras (sotorasib) to treat non-small-cell lung cancer
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Marketing Network
MARCH 2, 2022
Tune in to this episode of the Pharma Marketing Podcast to hear a discussion with Charles Benaiah, Innovator, Founder and CEO of Watzan, Founder of ililli , and Jennifer Ginest, Digital Marketing Manager of PMN on audio and the possibilities of integrating it into your marketing strategy.
pharmaphorum
FEBRUARY 28, 2022
With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available. However, as Ben Hargreaves discovers, research into the area has only scratched the surface, amid calls for greater funding and greater collaboration to accelerate progress. There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition.
Outsourcing Pharma
MARCH 3, 2022
This monthâs announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.
Pharma Times
MARCH 2, 2022
The post-Brexit landscape has witnessed an exponential boom in life science careers
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Roots Analysis
MARCH 2, 2022
Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies.
pharmaphorum
MARCH 4, 2022
The pharmaceutical industry is still picking its way through the debris of the pandemic but the gloom can be illuminated by the power of coaching to drive connections and value. It is clear that sales forces and MSL teams need to enhance their skills to make every second of their precious time in front of HCPs count. They are facing unprecedented challenge as traditional routes evaporate which means they need to be pitch perfect when they have a window of attention either in person or across dig
Pharma Mirror
MARCH 2, 2022
MONTGOMERY, Ala. and PRINCETON, N.J. and LONDON and BANGALORE, India, Aedesius Health, a division of AedesiusOne Ltd, and its biopharmaceutical development incubator AO BIO, which is focused on developing and commercializing neglected and needed therapies, devices, and diagnostics, today announced a comprehensive commercialization partnership with Indegene, a technology-led healthcare solutions provider.
Pharma Times
FEBRUARY 28, 2022
Quviviq can be used on a long-term basis, addressing a key limitation of existing therapies
Pharma Marketing Network
MARCH 2, 2022
Tune in to this episode of the Pharma Marketing Podcast to hear a discussion with Charles Benaiah, Innovator, Founder and CEO of Watzan, Founder of ililli , and Jennifer Ginest, Digital Marketing Manager of PMN on audio and the possibilities of integrating it into your marketing strategy. The post Ep. 19: Let’s Talk “TALK and Pharma” – Jennifer Ginest and Charles Benaiah, Founder of Watzan and ililli appeared first on Pharma Marketing Network.
pharmaphorum
MARCH 3, 2022
Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with the condition. The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 da
Pharma Mirror
MARCH 2, 2022
Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it had reached agreement with Novartis to acquire its Ringaskiddy campus (Novartis Ringaskiddy Limited), near Cork, Ireland. Financial details of the sale, which is expected to close in Q4, 2022, have not been disclosed. Under the terms of the agreement, Sterling will acquire the 111-acre site, which includes three active pharmaceutical ingredient (API) manufacturing buildings, as well a
Roots Analysis
MARCH 1, 2022
The intranasal route of administration is widely accepted as effective and non-invasive option for the local and systemic delivery of several types of active pharmaceutical ingredients (API). Majority of such formulations are designed to treat chronic obstructive pulmonary disorders (COPD), asthma and other respiratory diseases. Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations.
Pharma Marketing Network
MARCH 2, 2022
New findings from an IQVIA report show the biopharmaceutical industry is sparking with activity with an astounding 6,000 products in development and new geographical locations seeing the boom. While it was a concern that COVID-19 would slow down new ventures in the biopharmaceutical sector, the reality has been just the opposite. According to Murray Aitken, IQVIA’s Senior VP and Executive Director of the IQVIA Institute for Human Data Science, “the pandemic has accelerated biopharmac
pharmaphorum
FEBRUARY 28, 2022
A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common “mass market” conditions. The analysis by IQVIA and pharma company Chiesi looked at the per patient, per year (PPPY) direct, indirect and mortality-related costs associated with 24 rare diseases, and compared them to 24 chronic ailments like diabetes, heart disease, arthritis and cancers.
Pharma Mirror
MARCH 2, 2022
While most only really know the basics of Social Security, this administration is an insurance program that provides families and individuals with the necessary information and tools to obtain financial stability. However, claiming Social Security disability benefits can be time-consuming. Moreover, claims are sometimes rejected due to minor errors.
Fuld
FEBRUARY 28, 2022
Competitive Intelligence [CI] has gone through an evolution since becoming a corporate function nearly 4 decades ago. Once viewed as a niche area handled by somebody with the background of a CIA operative, we have seen tremendous growth in businesses adopting and implementing best practices to change how work is done and how intelligence is applied to business issues.
Roots Analysis
FEBRUARY 28, 2022
Over the past few years, the pharmaceutical industry is growing a tremendous pace. Considering patient’s health and safety, the drug products are expected to be free from microbial contamination and should be safe for use throughout the drug’s life cycle. Therefore, several quality checks are performed to ensure product’s sterility and stability. One of the stages that require quality assurance is packaging of the drug product, as compromised packaging could have serious consequences.
pharmaphorum
MARCH 4, 2022
New survey data from Press Ganey suggests that pharma may be able to get an edge by integrating physician directories into brand websites. When it comes to pharma marketing, historically companies have had to either market direct to consumers — and trust them to find a doctor and bring up the company’s product with them — or to send sales reps to doctors — and hope they had the right mix of potential customers among their patients.
Outsourcing Pharma
FEBRUARY 28, 2022
Ergomed, a global contract research organization, is partnering with Trialbee to improve patient recruitment at its new Rare Disease Innovation Center.
Expert insights. Personalized for you.
135 
Let's personalize your content